Internal Medicine, Interventional Cardiology · Lafayette, LA
NPI
1427254432
Since 2007
Specialty
Internal Medicine, Interventional Cardiology
Code 207RI0011X
Group practices
7
Medicare group memberships
Hospitals
5
Hospital affiliations
441 Heymann Blvd
Lafayette, LA, 70503
Phone (337) 289-8429
Groups this clinician bills Medicare through
Medicare paid, 2024
$1.3M
15,615 services
Medicare patients, 2024
2,776
Average age 75
Drug cost, 2024
$2.8M
27,637 prescriptions
Company payments, 2025
$4,359
From 21 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Agostino Ingraldi was code 93000 (electrocardiogram), 2,652 times for 2,108 patients. In total Agostino Ingraldi billed 15,615 services in 138 codes, and Medicare paid $1.3M.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2020-10-20.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 93000 Electrocardiogram | Office | 2,652 | 2,108 | $9.91 | $26K |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 2,062 | 1,545 | $12.15 | $25K |
| 99214 Office E&M - Established | Office | 1,920 | 1,459 | $89.69 | $172K |
| 99490 Chronic, Principal, and Transitional Care Management | Office | 730 | 76 | $46.08 | $34K |
| 80061 Clinical Chemistry | Office | 657 | 596 | $13.12 | $8,620 |
| 93306 Echocardiography (TTE/TEE) | Office | 538 | 513 | $131.03 | $70K |
| 93880 Duplex Scan - Extracranial Arteries | Office | 444 | 436 | $129.80 | $58K |
| J2785 Injection, regadenoson, 0.1 mg | Office | 413 | 104 | $6.88 | $2,840 |
| 80053 Clinical Chemistry | Office | 363 | 338 | $10.35 | $3,757 |
| A9555 Rubidium rb-82, diagnostic, per study dose, up to 60 millicuries | Office | 334 | 236 | $417.26 | $139K |
| 84450 Clinical Chemistry | Office | 306 | 285 | $5.08 | $1,554 |
| 84460 Clinical Chemistry | Office | 306 | 285 | $5.19 | $1,588 |
| 84075 Clinical Chemistry | Office | 305 | 284 | $5.08 | $1,549 |
| 93018 Electrocardiogram | Office | 284 | 272 | $10.70 | $3,038 |
| 78434 Myocardial Perfusion Scan | Office | 255 | 255 | $489.48 | $125K |
By year: 2022 $1.3M for 16,427 services; 2023 $1.1M for 14,481 services; 2024 $1.3M for 15,615 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 80061 Clinical Chemistry | 657 | 596 | $13.12 | $8,620 |
| 80053 Clinical Chemistry | 363 | 338 | $10.35 | $3,757 |
| 84450 Clinical Chemistry | 306 | 285 | $5.08 | $1,554 |
| 84460 Clinical Chemistry | 306 | 285 | $5.19 | $1,588 |
| 84075 Clinical Chemistry | 305 | 284 | $5.08 | $1,549 |
| 80048 Clinical Chemistry | 112 | 105 | $8.29 | $928 |
| 85027 Blood Count | 70 | 65 | $6.34 | $444 |
| 84443 Clinical Chemistry | 15 | 14 | $16.46 | $247 |
| 83880 Clinical Chemistry | 13 | 13 | $36.58 | $475 |
Medicare prescription drug claims, 2024
In 2024, the drug Agostino Ingraldi prescribed most often to Medicare patients was Rosuvastatin Calcium, with 4,231 prescriptions and refills. In total Agostino Ingraldi wrote 27,637 Medicare prescriptions that cost $2.8M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Rosuvastatin Calcium Generic | 4,231 | 9,268 | 1,017 | $55K |
| Atorvastatin Calcium Generic | 1,953 | 4,492 | 516 | $19K |
| Ezetimibe Generic | 1,913 | 3,910 | 456 | $33K |
| Amlodipine Besylate Generic | 1,621 | 3,363 | 407 | $7,022 |
| Metoprolol Succinate Generic | 1,596 | 3,382 | 385 | $20K |
| Eliquis Apixaban | 1,114 | 1,613 | 215 | $913K |
| Furosemide Generic | 971 | 1,808 | 259 | $2,970 |
| Carvedilol Generic | 915 | 2,016 | 228 | $6,766 |
| Xarelto Rivaroxaban | 730 | 1,132 | 129 | $620K |
| Clopidogrel Clopidogrel Bisulfate | 696 | 1,570 | 177 | $7,099 |
| Lisinopril Generic | 677 | 1,540 | 171 | $3,972 |
| Losartan Potassium Generic | 623 | 1,367 | 169 | $6,023 |
| Valsartan Generic | 602 | 1,303 | 151 | $15K |
| Nifedipine Er Nifedipine | 590 | 1,239 | 143 | $15K |
| Hydrochlorothiazide Generic | 544 | 1,142 | 137 | $1,518 |
Brand drugs: - claims; generic drugs: 24,139 claims; opioid claims: 13.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Agostino Ingraldi $4,359 ($4,359 in general payments such as food, travel and fees) from 21 companies. The largest payer was Boehringer Ingelheim Pharmaceuticals, Inc. with $1,323.
| Company | Payments | Amount |
|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. | 5 | $1,323 |
| Lilly USA, LLC LLY | 3 | $1,271 |
| Kestra Medical Technology Services, Inc. | 9 | $355 |
| Novartis Pharmaceuticals Corporation NVS | 15 | $272 |
| Abiomed JNJ | 12 | $173 |
| Medtronic, Inc. MDT | 1 | $155 |
| Shockwave Medical, Inc JNJ | 4 | $154 |
| Bard Peripheral Vascular, Inc. BDX | 1 | $152 |
| E.R. Squibb & Sons, L.L.C. BMY | 7 | $117 |
| Pfizer Inc. PFE | 3 | $72.01 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.